Tolvaptan: Phase III data

In the double-blind, placebo-controlled, international Phase III EVEREST trial in 4,133 patients, long-term therapy with 30 mg of once-daily

Read the full 199 word article

How to gain access

Continue reading with a
two-week free trial.